Pacific Biosciences Appoints Kathy Ordoñez as Chief Commercial Officer
Thursday, November 2, 2017
Ms. Ordoñez brings more than thirty years of experience in the life sciences and diagnostics industries, with senior roles at Hoffmann-La Roche,
“I have worked with Kathy since the early days of PCR commercialization, and I am pleased that she has agreed to bring her substantial experience to our commercial endeavors,” said
As Chief Commercial Officer, Ms. Ordoñez will have senior responsibility for the Company’s sales, support, and marketing operations and remain a member of its Board of Directors. She will report to Chairman and CEO
Kathy holds a Bachelor’s degree in chemistry/physics and a Doctorate of Science (Honorary) from
About Pacific Biosciences
real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
All statements in this press release that are not historical are forward-looking statements,
including, among other things, statements relating to future availability, uses, quality or performance of, or benefits of using, products or technologies, the company’s commercial capability or market presence, the suitability of the company’s products for particular applications or markets and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent
reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
News Provided by Acquire Media